GPR3 was evaluated because it was described as being down-regulated in RRMS patients who have a poor disease course [21], and has therefore been patented for the prediction of MS prognosis by Achiron and Gurevich [81]. This evidence concerns the gene GPR3 and myeloid sarcoma.